Observation of Efficacy and Safety of Converting the Calcineurin Inhibitor to Sirolimus in Renal Transplant Recipients With Chronic Allograft Nephropathy

Transplantation Proceedings

Volumn 40, Issue 5, 2008, Pages 1411-1415

  Chen, J ^a   Li, L ^a   Wen, J ^a   Tang, Z ^a   Ji, S ^a   Sha, G ^a   Cheng, Z ^a   Sun, Q ^a   Cheng, D ^a   Liu, Z ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CHOLESTEROL; COMPLEMENT COMPONENT C4D; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL; URIC ACID;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CAPILLARY; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; COMPLEMENT DEPOSITION; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; KIDNEY BIOPSY; LEUKOCYTE COUNT; LEUKOPENIA; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; URIC ACID BLOOD LEVEL;

ADULT; CALCINEURIN; CHRONIC DISEASE; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PLATELET COUNT; PREDNISOLONE; SAFETY; SIROLIMUS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 45449115373     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.096     Document Type: Article

References (24)

1. Racusen C., Solez K., Colvin R.B., et al. The Banff97 working classification for renal allograft pathology. Kidney Int 55 (1999) 713
2. Halloran P.F. Molecular mechanisms of new immunosupressants. Clin Transplant 10 (1996) 118
3. Muthukkumar S., Ramesh T., and Bondada S. Rapamune, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 60 (1995) 264
4. Vazquez M.A. Chronic rejection of renal transplants: new clinical insights. Am J Med 0 Sci 320 (2000) 43
5. Martin K.A., Rzucidlo E.M., Merenick B.L., et al. The mTOR/p70S6K1 pathway regulates vascular smoogh muscle cell differentiation. Am J Physiol Cell Physiol 286 (2004) c507
6. Morales J.M., Campistol J.M., Kreis H., et al. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. Transplant Proc 37 (2005) 693
7. Gallo R., Padurean A., Jayaraman T., et al. Inhivition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99 (1999) 2164
8. Kawamata S., Sakaida H., Hori T., et al. The up-regulation of p27Kipl by rapamycin results in GL arrest in exponentially growing T-cell lines. Blood 91 (1998) 561
9. Waller J.R., Brook N.R., Bicknell G.R., et al. Differential effects of modem immunosuppressive agents on the development of intimal hyperplasia. Transplant Int 17 (2004) 9
10. Simm A., Nestler M., and Hoppe V. PDGF-AA, a present mitogen for cardiac fibroblasts from adult rats. J Mol Cell Cardiol 29 (1997) 357
11. Shihab F.S., Tanner A.M., Shao Y., et al. Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 50 (1996) 1904
12. Jolicoeur E.M., Qi S., Xu D., et al. Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. Transplantation 75 (2003) 54
13. Cittero F., Scata M.C., Violi P., et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 35 (2003) 1292
14. Kahan B.D. Rapamcin: personal algorithms for use based on 250 treated renal allograft recipients. Transplant Proc 30 (1998) 2185
15. Pescovitz M., and Govani M. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. Am J Kidney Dis 38 suppl 2 (2001) S16
16. Flcchner S.M., Goldfarb D., Modlin C., et al. Kidney transplantation without calcincurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74 (2002) 1070
17. Wistson C.J., Firth J., Williams P.F., et al. A randomized controlled trial of late conversion from CNI-base to sirolimus-based immunosuppression following renal transplantation. Am J Tansplant 5 (2005) 2496
18. Chuch S.C., and Kahan B.D. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 76 (2003) 375
19. Mathis A.S., Dave N., Knipp G.T., et al. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 61 (2004) 565
20. Morrisett J.D., Abdel-Fattah G., and Kahan B.D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 35 3 suppl (2003) 143s
21. Varghese Z., Femando R., Moorhead J.F., et al. Effects of Sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts. Am J Physiol Renal Physiol 289 (2005) F43
22. Niemczyk M., Wyzgal J., Perkowska A., et al. Sirolimus-associated hepatotoxicity in the kidney graft recipient. Transpl Int 18 (2005) 1302
23. Takemoto S.K., Zeevl A., Feng S., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 4 (2004) 1033
24. Regele H., Bohming G.A., Habicht A., et al. Capillary deposition of complement split product C4d in renal allograft is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 13 (2002) 2371